Drug Trial Radar · NCT01709578
To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)
Last checked: Nov 20, 2026Latest source record: Aug 8, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
546
Actual
Start
Oct 2012
Primary completion
Mar 2015
Study completion Mar 2015
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- Collaborators
- Regeneron Pharmaceuticals
- First posted
- Oct 18, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective: To demonstrate that sarilumab added to disease modifying anti-rheumatic drugs (DMARDs) were effective for: * reduction of signs and symptoms at Week 24 and * improvement of physical function at Week 12 in participants with active rheumatoid arthritis (RA) who were inadequate responders or intolerant to tumor necrosis factor alpha (TNF-α) antagonists. Secondary Objectives: The secondary objectives were to investigate the effects of SAR153191 (REGN88) when added to DMARD therapy, in participants with active RA who were inadequate responders or intolerant to TNF-α antagonists, for: * Reduction of signs and symptoms at Week 12; * Improvement in physical function at Week 24; * Improvement in disease activity score as measured by other American College of Rheumatology (ACR) derived components at Weeks 12 and 24; * Improvement in quality of life as measured by participant reported outcomes (PROs) at intermediate visits and Week 24. To assess the exposure of sarilumab added to DMARD therapy in this population. To assess the safety of sarilumab in this population.
Conditions
- Rheumatoid Arthritis
Interventions
SarilumabDrug
Pharmaceutical form:solution Route of administration: subcutaneous
placeboDrug
Pharmaceutical form:solution Route of administration: subcutaneous
hydroxychloroquineDrug
Dispensed according to the local practice.
methotrexateDrug
Dispensed according to the local practice.
sulfasalazineDrug
Dispensed according to the local practice.
leflunomideDrug
Dispensed according to the local practice.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Achieved at Least 20% Improvement in the American College of Rheumatology (ACR20) Criteria at Week 24Time frame: Week 24
- Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 12Time frame: Baseline, Week 12
Locations
196 sites in 30 countries. Site status is shown where the registry gives one.
Investigational Site Number 840070
Anniston, Alabama
Investigational Site Number 840138
Birmingham, Alabama
Investigational Site Number 840142
Phoenix, Arizona
Investigational Site Number 840134
Fullerton, California
Investigational Site Number 840141
Glendale, California
Investigational Site Number 840111
La Jolla, California
Investigational Site Number 840135
San Diego, California
Investigational Site Number 840021
Santa Maria, California
Investigational Site Number 840100
Stanford, California
Investigational Site Number 840049
Upland, California
Investigational Site Number 840131
Whittier, California
Investigational Site Number 840201
Denver, Colorado
Investigational Site Number 840130
Lewes, Delaware
Investigational Site Number 840125
DeBary, Florida
Investigational Site Number 840048
Miami, Florida
Investigational Site Number 840024
Naples, Florida
Investigational Site Number 840006
Orlando, Florida
Investigational Site Number 840128
Ormond Beach, Florida
Investigational Site Number 840063
Palm Harbor, Florida
Investigational Site Number 840060
Sarasota, Florida
Investigational Site Number 840140
Tampa, Florida
Investigational Site Number 840126
Vero Beach, Florida
Investigational Site Number 840018
Idaho Falls, Idaho
Investigational Site Number 840110
Meridian, Idaho
Investigational Site Number 840052
Kansas City, Kansas
Investigational Site Number 840015
Lexington, Kentucky
Investigational Site Number 840120
Baton Rouge, Louisiana
Investigational Site Number 840109
Lake Charles, Louisiana
Investigational Site Number 840055
Frederick, Maryland
Investigational Site Number 840150
Lansing, Michigan
Investigational Site Number 840137
Saint Clair Shores, Michigan
Investigational Site Number 840037
Tupelo, Mississippi
Investigational Site Number 840112
Lincoln, Nebraska
Investigational Site Number 840106
Orchard Park, New York
Investigational Site Number 840121
Rochester, New York
Investigational Site Number 840115
Roslyn, New York
Investigational Site Number 840118
Smithtown, New York
Investigational Site Number 840139
Syracuse, New York
Investigational Site Number 840123
Charlotte, North Carolina
Investigational Site Number 840116
Wilmington, North Carolina
Showing 40 of 196 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.